|Articles|October 7, 2021

Supplements and Featured Publications

  • Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

This publication was funded and developed by United Therapeutics.

This AJMC® Clinical Brief summarizes results of the pivotal study by Aaron Waxman MD, PhD, et al published in The New England Journal of Medicine on the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo